Neil M. Iyengar, MD

Articles

Unmet Needs and Future Outlook for HER2-Targeted Therapies

December 4th 2025

Panelists discuss how innovative HER2-targeted strategies and precision approaches will define the next era of breast cancer therapy.

Exciting New Data for TNBC Therapies

December 4th 2025

Panelists discuss how new trial results from ASCENT-03 and TROPION-Breast02 are shaping next-generation TNBC therapies.

Disease State Information on TNBC

November 25th 2025

Panelists discuss how molecular characterization and novel agents are redefining the management of TNBC.

Treatment of HER2-Low and Future Therapies in Metastatic Breast Cancer

November 25th 2025

Panelists discuss how HER2-low and HER3-directed therapies are expanding precision treatment opportunities in metastatic breast cancer.

Ongoing Research to Watch in TNBC

November 19th 2025

Panelists spotlight key trials and drugs to watch in ongoing research in triple-negative breast cancer.

Highlighting Additional Key TNBC Data From ESMO 2025

November 19th 2025

Panelists break down other key triple-negative breast cancer data presented at the 2025 ESMO Congress.

Additional Data with HER2-Targeted Agents in Metastatic Breast Cancer

November 18th 2025

Panelists discuss how newer HER2-targeted therapies show promise for CNS disease control and broader metastatic management.

Treatment Sequencing in Later Lines of Therapy in HER2+ Metastatic Breast Cancer

November 18th 2025

Panelists discuss how thoughtful sequencing of HER2-targeted agents maximizes benefit and extends survival in metastatic settings.

Findings for Frontline Dato-DXd From TROPION-Breast02 in Immunotherapy-Ineligible TNBC

November 12th 2025

Panelists discuss findings from the TROPION-Breast02 trial evaluating first-line datopotamab deruxtecan in immunotherapy-ineligible triple-negative breast cancer.

Addressing Sequencing Questions With TROP-2–Directed ADCs in TNBC

November 12th 2025

Panelists discuss sequencing considerations as more TROP-2–directed antibody-drug conjugates are evaluated in triple-negative breast cancer.

First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

November 11th 2025

Panelists discuss how evolving first-line HER2-targeted combinations are improving outcomes and redefining standards in metastatic breast cancer..

The Role of ADCs in Different Subgroups

November 11th 2025

Panelists discuss how ADCs are revolutionizing HER2-targeted therapy through precision delivery and improved tolerability across patient subgroups.

Safety Profile of Sacituzumab Govitecan–Based Treatment in Frontline TNBC

November 5th 2025

Panelists discuss safety considerations for sacituzumab govitecan–based therapy in frontline triple-negative breast cancer.

ASCENT-03: Data for Frontline Sacituzumab Govitecan in IO-Ineligible TNBC

November 5th 2025

Panelists highlight findings from the ASCENT-03 trial evaluating sacituzumab govitecan in triple-negative breast cancer ineligible for immunotherapy.

Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

November 3rd 2025

Panelists discuss how new trial data are optimizing early-stage HER2-positive breast cancer treatment through refined, evidence-based regimens.

Background Information on Targeted Therapies in Breast Cancer

November 3rd 2025

Panelists discuss how the evolution of HER2 testing and classification has redefined treatment strategies and expanded therapeutic opportunities in breast cancer.

Contextualizing Data for Frontline Sacituzumab Govitecan Plus Pembrolizumab in PD-L1+ TNBC

October 30th 2025

Panelists break down data from the ASCENT-04 trial evaluating sacituzumab govitecan plus pembrolizumab in triple-negative breast cancer.

Current Frontline Treatment Approaches and Challenges in Advanced TNBC

October 30th 2025

Panelists discuss the current state of the frontline treatment paradigm for advanced triple-negative breast cancer

SABCS Highlights and Future Directions in the Treatment of Breast Cancer

February 26th 2025

Panelists discuss how the continued evolution of HER2-directed therapies, particularly the expanding role of trastuzumab deruxtecan (T-DXd) across different breast cancer settings, has transformed the treatment landscape, while emphasizing the importance of appropriate patient selection, optimal sequencing strategies, and the need for education around early adoption of promising therapies in community practice settings.

Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer

February 26th 2025

Panelists discuss how emerging data from trials such as DESTINY-Breast09, which is evaluating first-line trastuzumab deruxtecan (T-DXd) with or without pertuzumab, could potentially reshape the treatment paradigm for HER2+ metastatic breast cancer (mBC) by establishing new standards for initial therapy and optimal combination approaches.